Clinical Evidence & Publications
-Tirzepatide Efficacy: The SURMOUNT-1 Trial (Jastreboff et al., NEJM) demonstrated that Tirzepatide resulted in substantial weight reduction (up to 20.9%) in adults with obesity.
-Incretin Hormone Mechanism: Seino et al. GIP and GLP-1, the Two Incretin Hormones. Describes GIP and GLP-1 as the two primary incretin hormones released from the intestine after nutrient intake and involved in glucose-dependent insulin secretion. https://pmc.ncbi.nlm.nih.gov/articles/PMC4020673/
– Glycine Mechanism: Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. Reviews glycine’s role as a precursor for key metabolites including creatine, glutathione, heme, purines, and porphyrins. https://pmc.ncbi.nlm.nih.gov/articles/PMC5350494/
-Collagen Structure Mechanism: Proline Precursors and Collagen Synthesis: Biochemical Challenges of Nutrient Supplementation and Wound Healing. Describes collagen as approximately one-third glycine, with glycine appearing at every third amino acid position in the collagen structure. https://pmc.ncbi.nlm.nih.gov/articles/PMC5657141/
-Neurological Signaling Mechanism: National Center for Biotechnology Information (NCBI), Basic Neurochemistry: Glycine Receptors. Describes glycine as a major inhibitory neurotransmitter in the central nervous system, especially the spinal cord. https://www.ncbi.nlm.nih.gov/books/NBK28003/
-Metabolic Pathways Mechanism: Glycine Metabolism and Its Alterations in Obesity and Metabolic Diseases. Reviews glycine’s involvement in biological functions including synthesis of glutathione, purines, creatine, heme-related compounds, and primary bile acids. https://pmc.ncbi.nlm.nih.gov/articles/PMC6627940/
Footer Disclaimer
> Important Safety Information: TRTBOSS facilitates access to medical services provided by independent, licensed physicians. This program utilizes Compounded Tirzepatide combined with Glycine. This is a compounded medication and is not FDA-approved. It is not a generic version of Zepbound™ or Mounjaro™. Compounded medications are prepared by licensed pharmacies to meet individual patient needs and do not undergo FDA review for safety, efficacy, or manufacturing quality. Claims regarding the safety or efficacy of this specific compounded combination have not been evaluated by the FDA. WARNING: Tirzepatide has been associated with thyroid C-cell tumors in animal studies. Do not use if you have a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Risks include nausea, pancreatitis, and gallbladder disease. Rx Only.